ArticleRheumatology international2017
Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective.
Article in Rheumatology international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Systematic review of quantitative preference studies of treatments for rheumatoid arthritis among patients and at-risk populations.Arthritis research & therapy · 2022Pooled it
- Preferences for Tapering Biologic Disease-Modifying Antirheumatic Drugs Among People With Rheumatoid Arthritis: A Discrete Choice Experiment.Arthritis care & research · 2025Article
- Relative Importance of Disease-Modifying Antirheumatic Drug Attributes for Patients with Rheumatoid Arthritis.Patient preference and adherence · 2025Article
- Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia.Clinical rheumatology · 2024Article
- Physical function and severe side effects matter most to patients with RA (< 5 years): a discrete choice experiment assessing preferences for personalized RA treatment.BMC rheumatology · 2023Article
- Psychosocial Factors Are Associated With Risk Acceptance in Upper Extremity Patients.Hand (New York, N.Y.) · 2022Article
- Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis.Clinical rheumatology · 2022Article
- Dynamics of Patient-Based Benefit-Risk Assessment of Medicines in Chronic Diseases: A Systematic Review.Patient preference and adherence · 2022Review
- A Systematic Review of Discrete Choice Experiment Studies in Rheumatoid Arthritis Biological Medicines.Mediterranean journal of rheumatology · 2021Review
- Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review.Patient preference and adherence · 2021Review
- Patient preferences on rheumatoid arthritis second-line treatment: a discrete choice experiment of Swedish patients.Arthritis research & therapy · 2020Article
- Patients' expectations and experiences of stem cell therapy for the treatment of knee osteoarthritis.Health expectations : an international journal of public participation in health care and health policy · 2020Article
- Tapering Biologic Therapy for Rheumatoid Arthritis: A Qualitative Study of Patient Perspectives.The patient · 2020Article
- Assessing disease severity in bio-naïve patients with RA on treatment with csDMARDs: insights from the Corrona Registry.Clinical rheumatology · 2020Article
- Patient preferences for rheumatoid arthritis treatment.Current opinion in rheumatology · 2019Review
- Patient and physician preferences for attributes of biologic medications for severe asthma.Patient preference and adherence · 2019Article
- Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment.Patient preference and adherence · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the increasing number of available treatments for rheumatoid arthritis (RA) with varying efficacy and safety profiles, it is critical to understand the level of trade-offs that patients are willing to make between benefits and risks. Adult patients with moderate to severe RA were invited to participate in a discrete choice experiment that solicited their preferences for hypothetical RA treatments. Each participant was presented with 14 choice cards asking about their preference between two hypothetical RA treatments with varying levels of efficacy, adverse events, and process-related attributes. A multivariable logistic regression model assessed the association between the attributes and the patient's decision and risk-increases were calculated. 510 eligible patients with moderate to severe RA completed the study. The average age of the participants was 56.4 years, 64.7% were female, and 45.1% received biologic agents. To achieve a 50% improvement in physical function, patients were willing to accept risk-increases of 91.1, 4.7, and 18.4% for abnormal laboratory results, cancer, and serious infection, respectively. Similarly, to achieve a 50% reduction in RA-related pain, patients were willing to accept risk-increases of 70.6, 3.7, and 14.2% for each AE. Moreover, patients were willing to trade risk-increases of 42.0, 2.2, and 8.5% for each AE to obtain a 50% reduction in the number of swollen joints. Patients with moderate to severe RA are willing to accept increased treatment risks to achieve improved physical function and disease control. These attributes are helpful to clinicians to make informed treatment choices.
Indexed as
Identifiers
28623526What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.